FDA Issues Qualified Health Claim Related to Yogurt, Type 2 Diabetes
By Denny Jacob
The U.S. Food and Drug Administration doesn't intend to object to certain health claims surrounding yogurt and type 2 diabetes.
The FDA said in a letter of enforcement discretion that it won't object to certain qualified health claims related to yogurt consumption and reduced risk of type 2 diabetes provided that the qualified health claims are worded in a way that doesn't mislead consumers, among other considerations.
A qualified health claim is supported by scientific evidence but doesn't meet the more rigorous "significant scientific agreement" standard required for an authorized health claim, the regulator said.
The FDA responded to a qualified health claim petition submitted on behalf of Danone North America. After reviewing the petition and other evidence related to the claim, it determined that there is some credible evidence supporting a relationship between yogurt intake and reduced risk of type 2 diabetes but that the evidence is limited.
"We know that a growing body of research suggests regular yogurt consumption could reduce your risk of developing one of the most significant and rapidly rising health ailments in the United States. That's why we decided to submit a petition for this first-of-its-kind qualified health claim," said Miguel Freitas, vice president of health and scientific affairs at Danone North America.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
March 01, 2024 15:57 ET (20:57 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
Magnificent 7 Stocks Earnings Updates: AI Remains the Focus
-
Small-Cap and Value Stocks Are Undervalued
-
Why We Expect the Job Market’s Slowdown to Renew in 2024
-
5 Undervalued Stocks to Buy to Play a Little Defense
-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Amazon Earnings: AWS Growth Accelerates and Profit Margins Improve
-
SiriusXM Earnings: Decent Results With Plan for Technology and Content Investment to Drive Growth
-
Coca-Cola Earnings: Solid Volume On Innovation and Digital Engagement
-
Is Berkshire Hathaway a Buy Before the Annual Meeting?
-
Investment Opportunities in the Drug Distribution Industry
-
Why the End of Quantitative Tightening Matters
-
Eli Lilly Earnings: Strong Weight-Loss Drug Sales Expand Margins
-
After Earnings, Is Meta Stock a Buy, a Sell, or Fairly Valued?